Compare · NEUP vs NVO
NEUP vs NVO
Side-by-side comparison of Neuphoria Therapeutics Inc. (NEUP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NEUP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $172.11B, about 13709.5x NEUP ($12.6M).
- NVO has hit the wire 9 times in the past 4 weeks while NEUP has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for NEUP).
- Company
- Neuphoria Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $12.6M
- $172.11B
- 1M return
- -
- -0.41%
- 1Y return
- -
- -18.26%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NEUP
- SEC Form 8-K filed by Neuphoria Therapeutics Inc.
- SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
- SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
- SEC Form DEF 14A filed by Neuphoria Therapeutics Inc.
- SEC Form 10-K filed by Neuphoria Therapeutics Inc.
- SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.
- Neuphoria Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Control of Registrant, Regulation FD Disclosure, Financial Statements and Exhibits
- Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
- Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
- Neuphoria Therapeutics Inc. filed SEC Form 8-K: Other Events
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S